Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Chubb
Mallinckrodt
Fish and Richardson
Accenture
Chinese Patent Office
Fuji
Moodys
Teva

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,795,725

« Back to Dashboard

Summary for Patent: 8,795,725
Title:GABA analog prodrug sustained release oral dosage forms
Abstract: Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(.alpha.-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.
Inventor(s): Cundy; Kenneth C. (Redwood City, CA), Sastry; Srikonda (Sunnyvale, CA), Leung; Manshiu (Daily City, CA), Kadri; Balaji V. (Tampa, FL), Stach; Paul E. (Plymouth, MN)
Assignee: XenoPort, Inc. (Santa Clara, CA)
Application Number:11/269,045
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Composition; Use;

Drugs Protected by US Patent 8,795,725

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Arbor Pharms Llc HORIZANT gabapentin enacarbil TABLET, EXTENDED RELEASE;ORAL 022399-002 Dec 13, 2011 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS ➤ Try a Free Trial
Arbor Pharms Llc HORIZANT gabapentin enacarbil TABLET, EXTENDED RELEASE;ORAL 022399-002 Dec 13, 2011 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS ➤ Try a Free Trial
Arbor Pharms Llc HORIZANT gabapentin enacarbil TABLET, EXTENDED RELEASE;ORAL 022399-001 Apr 6, 2011 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS ➤ Try a Free Trial
Arbor Pharms Llc HORIZANT gabapentin enacarbil TABLET, EXTENDED RELEASE;ORAL 022399-001 Apr 6, 2011 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,795,725

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,906,412 GABA analog prodrug sustained release oral dosage forms ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,795,725

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2005301970 ➤ Try a Free Trial
Brazil PI0517227 ➤ Try a Free Trial
Canada 2584338 ➤ Try a Free Trial
China 101068538 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Daiichi Sankyo
McKinsey
UBS
Chubb
Cerilliant
Baxter
Merck
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.